TOTAL: $31.85M
Year to Date: $169.08M
Company
(Symbol)#*
Partner
(Country)
Amt.
(M)
Triggering
Event
Details (Date)

Basilea Pharmaceutica Ltd. (Switzerland; SWX:BSLN)Johnson & Johnson Pharmaceutical Research and Development LLCCHF24 ($19.6)Milestone paymentBasilea received the money for the filing of an NDA for ceftobiprole to treat complicated skin and skin structure infections (5/18)
CoGenesys Inc.*PDL BioPharma Inc. and Vegenics Ltd. (Australia)NDMilestone paymentCoGenesys achieved milestones for PDL's advancement of a candidate into preclinical testing and based on an agreement with Vegenics in the field of vascular endothelial growth factors (5/23)
CV Therapeutics Inc. (CVTX)Astellas Pharma U.S. Inc.$7Milestone paymentCV received the payment for the filing of an NDA for regadenoson as a stress agent in myocardial perfusion imaging tests (5/15)
Diversa Corp. (DVSA)BASF (Nachrichten/ Aktienkurs)NDMilestone paymentsDiversa achieved two milestones for completing the initial research phase of their collaboration and moving into the next development stage focused on discovering and optimizing new enzymes (5/16)
Medarex Inc. (MEDX)Amgen Inc. (AMGN)NDMilestone paymentMedarex will receive the payment for the advancement of an antibody into a Phase II clinical trial (5/3)
Neose Technologies Inc. (NTEC)Novo Nordisk A/S (Denmark)NDMilestone paymentNeose received the payment under a 2003 license agreement for the use of Neose's GlycoPEGylation technology to develop a next-generation version of Factor IX (5/24)
Progenics Pharmaceuticals Inc. (PGNX)Wyeth$4Milestone paymentProgenics received the payment after Wyeth filed for European approval of a subcutaneous formulation of methylnaltrexone for opioid-induced constipation (5/14)
SensiGen LLC*Ann Arbor SPARK$0.25InvestmentAnn Arbor SPARK approved the $250,000 investment in SensiGen from the Michigan Pre-Seed Capital Fund (5/15)
Sunesis Pharmaceuticals Inc. (SNSS)Merck & Co. Inc.$1Milestone paymentSunesis earned the payment for meeting a preclinical milestone in its collaboration to develop oral small-molecule inhibitors of beta-amyloid converting enzyme (5/2)

No Comments